NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP Investigating Claims on Behalf of Investors of DBV Technologies SA (“DBV” or the “Company”) DBVT. Those investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, extension 7980.

The investigation concerns whether DBV and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.

[Click here for information about joining the class action]

On October 26, 2021, DBV announced that it “received a notice from the FDA [U.S. Food and Drug Administration] concerning [DBV’s] Filing of STAMP record dated May 6, 2021.” The DBV informed investors that “[t]The FDA has requested a phased approach for DBV’s modified Viaskin Peanut (mVP) development program. The FDA wishes to review the data from the DBV protein uptake-release study before commenting further on the design of the STAMP protocol.”

As a result of this news, DBV’s share price fell $1.45 per share, or 28.71%, to close at $3.60 per share on October 27, 2021.

Then, on September 21, 2022, DBV announced that the FDA had partially clinically suspended its Phase 3 clinical trial evaluating its Viaskin peanut patch for the treatment of peanut allergy in children ages 4 to 7 and certain changes to elements the minutes of the negotiation.

As a result of this news, DBV’s stock price fell $0.18 per share, or 8.14%, to close at $2.03 per share on September 22, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris and Tel Aviv, is recognized as one of the leading law firms specializing in corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, best known as Dean of the Class Bar Association, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he founded and fights for the rights of victims of securities fraud, breaches of fiduciary duty and…